Janssen Pharmaceutical K.K. Sustainability Profile
Janssen Pharmaceutical K.K., a subsidiary of the global Johnson & Johnson family, is headquartered in Tokyo, Japan. Established in 1959, the company has made significant strides in the pharmaceutical industry, focusing on innovative solutions across various therapeutic areas, including oncology, immunology, and neuroscience. With a commitment to advancing healthcare, Janssen is renowned for its core products, such as treatments for chronic diseases and mental health disorders, which are distinguished by their efficacy and safety profiles. The company has solidified its market position through notable achievements, including the development of groundbreaking therapies that address unmet medical needs. Operating primarily in Japan and other key regions in Asia, Janssen Pharmaceutical K.K. continues to lead in research and development, striving to improve patient outcomes and enhance the quality of life for individuals worldwide.
DitchCarbon Score
How does Janssen Pharmaceutical K.K.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Janssen Pharmaceutical K.K.'s score of 78 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Janssen Pharmaceutical K.K., headquartered in Japan, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Johnson & Johnson, and as such, it inherits emissions data and climate commitments from its parent organisation. Janssen Pharmaceutical K.K. aligns its climate initiatives with those of Johnson & Johnson, which has set ambitious targets for reducing carbon emissions. These targets are part of the Science Based Targets initiative (SBTi) and include commitments to achieve significant reductions across its operations. The company is also involved in various sustainability initiatives, including the Carbon Disclosure Project (CDP) and the RE100 initiative, which focuses on transitioning to 100% renewable energy. While specific emissions figures for Janssen Pharmaceutical K.K. are not disclosed, the overarching goals and strategies from Johnson & Johnson indicate a strong commitment to addressing climate change and reducing carbon footprints across all scopes of emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 1990 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 308,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 751,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | - | - | - | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Janssen Pharmaceutical K.K.'s Industry?
How Carbon Intensive is Janssen Pharmaceutical K.K.'s Location?
Janssen Pharmaceutical K.K.'s Scope 3 Categories Breakdown
Janssen Pharmaceutical K.K.'s Scope 3 emissions, which decreased by 2% last year and increased significantly since 2011, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 72% of Scope 3 emissions.
Top Scope 3 Categories
Janssen Pharmaceutical K.K.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Janssen Pharmaceutical K.K. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
